BERKELEY, CA--(Marketwire - Feb 26, 2013) - Dynavax Technologies Corporation (
Dino Dina, M.D., Chief Executive Officer of Dynavax, will provide a company overview. To access the slide presentation, live webcast, and subsequent archived recording, please visit Dynavax's website at http://investors.dynavax.com/newsevents.cfm.
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. Dynavax's lead product candidate is HEPLISAV ™, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.